Roberto Stasi

15.8k total citations · 2 hit papers
161 papers, 9.7k citations indexed

About

Roberto Stasi is a scholar working on Hematology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Roberto Stasi has authored 161 papers receiving a total of 9.7k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Hematology, 36 papers in Pathology and Forensic Medicine and 32 papers in Genetics. Recurrent topics in Roberto Stasi's work include Platelet Disorders and Treatments (59 papers), Acute Myeloid Leukemia Research (52 papers) and Blood groups and transfusion (39 papers). Roberto Stasi is often cited by papers focused on Platelet Disorders and Treatments (59 papers), Acute Myeloid Leukemia Research (52 papers) and Blood groups and transfusion (39 papers). Roberto Stasi collaborates with scholars based in Italy, United Kingdom and United States. Roberto Stasi's co-authors include Sergio Amadori, Elisa Stipa, Drew Provan, Nichola Cooper, James B. Bussel, Giovanni Del Poeta, Maria Laura Evangelista, E. Terzoli, Douglas B. Cines and Terry Gernsheimer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Roberto Stasi

158 papers receiving 9.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

2008 1.9k citations Francesco Rodeghiero, Roberto Stasi et al. Blood profile →
Cancer‐related fatigue

2003 578 citations Roberto Stasi, Sergio Amadori et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roberto Stasi Italy	49	7.0k	1.9k	1.9k	1.5k	1.1k	161	9.7k
Robert McMillan United States	51	9.0k 1.3×	2.5k 1.3×	1.6k 0.9×	1.9k 1.3×	381 0.3×	131	10.7k
Peter A. McSweeney United States	44	3.9k 0.6×	938 0.5×	1.0k 0.6×	1.7k 1.2×	1.6k 1.4×	143	6.3k
Judith Marsh United Kingdom	52	6.6k 0.9×	352 0.2×	2.0k 1.1×	2.7k 1.8×	1.8k 1.6×	210	9.1k
Anneke Brand Netherlands	55	5.4k 0.8×	353 0.2×	1.4k 0.7×	2.3k 1.5×	988 0.9×	291	11.0k
Georgia B. Vogelsang United States	54	6.9k 1.0×	871 0.5×	1.8k 1.0×	3.2k 2.2×	1.9k 1.7×	141	10.4k
C Rozmán Spain	51	5.8k 0.8×	2.9k 1.5×	4.5k 2.4×	3.3k 2.3×	2.3k 2.0×	309	11.5k
Graham R.V. Hughes United Kingdom	68	4.3k 0.6×	2.5k 1.3×	748 0.4×	4.4k 3.0×	352 0.3×	263	18.2k
Jean‐Yves Cahn France	37	4.3k 0.6×	2.6k 1.4×	1.7k 0.9×	1.7k 1.1×	2.9k 2.5×	127	8.4k
Bernd Hertenstein Germany	40	3.6k 0.5×	687 0.4×	2.7k 1.4×	1.9k 1.3×	1.6k 1.4×	154	8.7k
Dominique Farge France	52	1.7k 0.2×	3.7k 2.0×	1.1k 0.6×	1.8k 1.2×	1.3k 1.1×	250	9.1k

Countries citing papers authored by Roberto Stasi

Since Specialization

Citations

This map shows the geographic impact of Roberto Stasi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Stasi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Stasi more than expected).

Fields of papers citing papers by Roberto Stasi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Stasi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Stasi. The network helps show where Roberto Stasi may publish in the future.

Co-authorship network of co-authors of Roberto Stasi

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto Stasi. A scholar is included among the top collaborators of Roberto Stasi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto Stasi. Roberto Stasi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cuker, Adam, Roberto Stasi, Jeffrey Palmer, et al.. (2014). Successful Detection and Management of Immune Thrombocytopenia in Alemtuzumab-Treated Patients with Active Relapsing-Remitting Multiple Sclerosis (P2.198). Neurology. 82(10_supplement). 3 indexed citations

Patel, Vivek, Matthieu Mahévas, Soo Yong Lee, et al.. (2012). Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 119(25). 5989–5995. 243 indexed citations

Gupta, Sahana, Joseph Onwude, Roberto Stasi, & Isaac Manyonda. (2012). Refusal of blood transfusion by Jehovah's Witness women: a survey of current management in obstetric and gynaecological practice in the U.K.. PubMed. 10(4). 462–70. 10 indexed citations

Amadori, Sergio, Roberto Stasi, Alberto M. Martelli, et al.. (2011). Temsirolimus, an mTOR inhibitor, in combination with lower‐dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML‐1107). British Journal of Haematology. 156(2). 205–212. 59 indexed citations

Poeta, Giovanni Del, Emanuele Ammatuna, Serena Lavorgna, et al.. (2010). The genotype nucleophosmin mutated and FLT3‐ITD negative is characterized by high bax/bcl‐2 ratio and favourable outcome in acute myeloid leukaemia. British Journal of Haematology. 149(3). 383–387. 10 indexed citations

Stasi, Roberto, Fenella Willis, Muriel S. Shannon, & E. C. Gordon‐Smith. (2009). Infectious Causes of Chronic Immune Thrombocytopenia. Hematology/Oncology Clinics of North America. 23(6). 1275–1297. 52 indexed citations

Stasi, Roberto, Nichola Cooper, Giovanni Del Poeta, et al.. (2008). Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell–depleting therapy with rituximab. Blood. 112(4). 1147–1150. 305 indexed citations

Rodeghiero, Francesco, Roberto Stasi, Terry Gernsheimer, et al.. (2008). Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 113(11). 2386–2393. 1853 indexed citations breakdown →

Stasi, Roberto & Drew Provan. (2008). Helicobacter pylori and Chronic ITP. Hematology. 2008(1). 206–211. 52 indexed citations

10.

Stasi, Roberto, Giovanni Del Poeta, Elisa Stipa, et al.. (2007). Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 110(8). 2924–2930. 231 indexed citations

11.

Stasi, Roberto, Elisa Stipa, Giovanni Del Poeta, et al.. (2006). Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Lara D. Veeken. 45(11). 1432–1436. 163 indexed citations

12.

Pacella, Claudio Maurizio, Giancarlo Bizzarri, Giampiero Francica, et al.. (2006). Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation. Journal of Hepatology. 44(5). 902–909. 35 indexed citations

13.

Amadori, Sergio, Stefan Suciu, Roberto Stasi, et al.. (2005). Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia. 19(10). 1768–1773. 63 indexed citations

14.

Stasi, Roberto, Sergio Amadori, Adrian C. Newland, & Drew Provan. (2005). Infliximab chimeric antitumor necrosis factor-α monoclonal antibody as potential treatment for myelodysplastic syndromes. Leukemia & lymphoma. 46(4). 509–516. 14 indexed citations

15.

Stasi, Roberto & Sergio Amadori. (2002). The Role of Angiogenesis in Hematologic Malignancies. Journal of Hematotherapy & Stem Cell Research. 11(1). 49–68. 10 indexed citations

16.

Stasi, Roberto & Sergio Amadori. (2002). Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. British Journal of Haematology. 116(2). 334–337. 15 indexed citations

17.

Stasi, Roberto, Giovanni Del Poeta, Adriano Venditti, et al.. (1998). AML-M0: a biological and clinical profile. Cineca Institutional Research Information System (Tor Vergata University). 4. 181–198. 2 indexed citations

18.

Stasi, Roberto, et al.. (1997). Serum levels of tumour necrosis factor-alpha predict response to recombinant humanerythropoietin in patients with myelodysplastic syndrome. Clinical & Laboratory Haematology. 19(3). 197–201. 8 indexed citations

19.

Stasi, Roberto, Adriano Venditti, Giovanni Del Poeta, et al.. (1996). High-dose chemotherapy in adult acute myeloid leukemia: Rationale and results. Leukemia Research. 20(7). 535–549. 14 indexed citations

20.

Cox, Maria Christina, Marcella Zollino, Giovanni Del Poeta, et al.. (1995). Trisomy 4 as the sole karyotypic anomaly in acute biphenotypic leukemia with B lineage markers and in acute minimally differentiated myeloid leukemia (MO). Cancer Genetics and Cytogenetics. 80(1). 66–67. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact